- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06319560
Hidroxicloroquina en la diabetes tipo 2 durante el embarazo
Mejora en el control de la glucosa con hidroxicloroquina en la diabetes tipo 2 durante el embarazo: un ensayo controlado aleatorio
The goal of this clinical trial is to compare the use of hydroxychloroquine as an adjunct to the current treatment of pregnant women with Type 2 diabetes mellitus.
The main questions it aims to answer are:
- Does hydroxychloroquine improve the pregnancy outcomes in women with type 2 diabetes during pregnancy?
- Does hydroxychloroquine improve the inflammatory markers in women with type 2 diabetes during pregnancy? Participants will be randomised into the intervention and control group. The control group will be on standard treatment where as the intervention group will receive hydroxychloroquine as an adjunct of standard treatment
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a randomised clinical trial comparing 2 groups i.e type 2 diabetes complicating pregnancies on standard treatment alone which comprises of oral hypoglycaemic agent with or without insulin and those with added hydroxychloroquine 200mg daily. They will be recruited within 14-20 weeks gestation. Randomisation will be done using computer software program. At recruitment, blood is withdrawn to measure glycated haemoglobin (HbA1c), full blood count, fructosamine, Interleukin-6, Interleukin-10 and Tumour Necrosis Factor-alpha. These investigations will be repeated before delivery. Patients will monitor their blood glucose using staggered 7 points which consisting of pre-meals and 1 hour post-meals using their own glucometer. The optimum fasting level is 4-5.3 mmol/l, pre meal and pre bed levels of 4-6 mmol/l and 1 hour post meal level of 4-7.8 mmol/l. All participants are followed up every 2-4 weekly whereby home blood glucose monitoring will be reviewed. Fetal growth will be monitored via serial ultrasound and charted on the fetal growth chart. Patients' care will be done by the research team which consist of obstetrician, endocrinologist and diabetic educator. All patients will have eye assessment by the ophthalmologist prior to commencement of hydroxychloroquine.
All women will be delivered at 38 weeks or earlier if there are other concomitant problems such as fetal growth restriction or poorly controlled diabetes via induction of labour. The details of the delivery for both mother and neonates will be documented. At birth, the offsprings will be seen by the neonatologist who is also in the research team. After delivery, participants will be followed up in research clinic at 6 and 12 months together with the neonate. The height and weight of the infants will be measured in centimeter. Developmental milestones will be assessed according to the developmental milestones chart of Paediatric Protocols for Malaysian Hospitals 4th Edition 2019.
Compliance to hydroxychloroquine will be assessed at each follow up, whereby an indirect method of assessing adherence of participants in the hydroxychloroquine group will be made. Each participant will be asked whether they are still taking the study medication and are required to bring the remaining medication for tablet count. Participants with remaining of more than 20% of the scheduled medications will be considered as non-compliance and treated as drop-out. Participants will also be considered as drop-out when they are lost to follow-up, withdrawal of consent, non-compliance to hydroxychloroquine or a patient becomes ill due to drug adverse effects.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Kuala Lumpur
-
Cheras, Kuala Lumpur, Malasia, 56000
- Antenatal clinic, UKM Medical Centre
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Singleton
- Pregnant women with a confirmed diagnosis of type 2 Diabetes Mellitus
Exclusion Criteria:
- autoimmune disease such as Systemic Lupus Erythematosus or rheumatic disease
- chronic kidney disease
- fetal anomaly
- women on steroid therapy
- diabetic retinopathy
- known thalassaemia or thalassaemia carrier
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Hydroxychloroquine group
Oral hydroxychloroquine 200mg daily will be prescribed to women in this group from recruitment (14-20 weeks) till delivery, in addition to their standard treatment |
200mg daily
Otros nombres:
|
|
Sin intervención: Standard treatment group
Women will receive standard treatment for diabetes such as metformin and insulin. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To compare the serum glycated haemoglobin (HbA1c) between the two groups
Periodo de tiempo: From Day 1 up to 38 weeks of gestation
|
Serum level of glycated haemoglobin (HbA1c) in percentage |
From Day 1 up to 38 weeks of gestation
|
|
To compare the serum fructosamine between the two groups
Periodo de tiempo: From Day 1 up to 38 weeks of gestation
|
Serum level of fructosamine in nanogram per milliliter |
From Day 1 up to 38 weeks of gestation
|
|
To compare the serum interleukin-6 between the two groups
Periodo de tiempo: From Day 1 up to 38 weeks of gestation
|
Serum level of interleukin-6 in nanogram per milliliter |
From Day 1 up to 38 weeks of gestation
|
|
To compare the serum interleukin-10 between the two groups
Periodo de tiempo: From Day 1 up to 38 weeks of gestation
|
Serum level of interleukin-10 in nanogram per milliliter |
From Day 1 up to 38 weeks of gestation
|
|
To compare the serum tumour necrosis factor alpha between the two groups
Periodo de tiempo: From Day 1 up to 38 weeks of gestation
|
Serum level of tumour necrosis factor alpha in nanogram per milliliter |
From Day 1 up to 38 weeks of gestation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To compare the gestational age at delivery between the two groups
Periodo de tiempo: From recruitment up to 38 weeks of gestation
|
Gestational age at delivery in weeks |
From recruitment up to 38 weeks of gestation
|
|
Type of labour
Periodo de tiempo: From recruitment up to 38 weeks of gestation
|
Onset of labour either spontaneous or induced |
From recruitment up to 38 weeks of gestation
|
|
Mode of delivery
Periodo de tiempo: From recruitment up to 38 weeks of gestation
|
Method of patient being delivered either vaginal or caesarean section |
From recruitment up to 38 weeks of gestation
|
|
Postpartum haemorrhage
Periodo de tiempo: Immediately from delivery up to 42 days post delivery
|
Total blood loss of more than 500 milliliters for vaginal delivery and 1000 milliliters for caesarean delivery |
Immediately from delivery up to 42 days post delivery
|
|
Obstetric anal sphincter injuries
Periodo de tiempo: Immediately from delivery up to 24 hours
|
The number of patients who suffered third or fourth degree perineal tear |
Immediately from delivery up to 24 hours
|
|
Neonatal birth weight at delivery
Periodo de tiempo: At delivery up to 24 hours
|
Birth weight of the neonate in grams, Neonatal birth weight of more than 90th percentile based on Fenton birth weight chart will be considered as large for gestational age or more than 4000 grams will be considered as macrosomia |
At delivery up to 24 hours
|
|
Shoulder dystocia
Periodo de tiempo: At delivery up to 24 hours
|
Number of patient who experienced shoulder dystocia at delivery |
At delivery up to 24 hours
|
|
Appearance, pulse, grimace, activity and respiration score of neonate at 5 minutes
Periodo de tiempo: At delivery up to 10 minutes after delivery
|
Number of neonates with Apgar score of less than 7 at birth which is bad outcome |
At delivery up to 10 minutes after delivery
|
|
Number of neonates needing admission into neonatal intensive care unit
Periodo de tiempo: At delivery up to 7 days of life
|
Admission of neonate into neonatal intensive care unit at birth |
At delivery up to 7 days of life
|
|
Height of the infant
Periodo de tiempo: At six and twelve months of age after delivery
|
Height or length of the infant measured in centimetres |
At six and twelve months of age after delivery
|
|
Weight of the infant
Periodo de tiempo: At six and twelve months of age after delivery
|
Weight of the infant measured in grams |
At six and twelve months of age after delivery
|
|
Hospital admission
Periodo de tiempo: From day 7 of life up to twelve months of age
|
Numbers of infants required hospital admission |
From day 7 of life up to twelve months of age
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Rahana Abd Rahman, UKM
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades del sistema endocrino
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades metabólicas
- Complicaciones del embarazo
- Trastornos del metabolismo de la glucosa
- Enfermedades Nutricionales y Metabólicas
- Diabetes Gestacional
- Diabetes Mellitus, Tipo 2
- Diabetes mellitus
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Quinolinas
- Aminoquinolinas
- Cloroquina
- Hidroxicloroquina
Otros números de identificación del estudio
- JEP-2023-866
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .